The effect of treatment package time in head and neck cancer patients treated with adjuvant radiotherapy and concurrent systemic therapy

Ahmed I. Ghanema,e,*, Matthew Schymicka, Souheyla Bachiria, Aniruddh Mannari, Jawad Sheqwarab, Charlotte Burmeister, Steven Chang, Tamer Ghanem, Farzan Siddiquia

Department of Radiation Oncology, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI 48202, USA
Department of Medical Oncology, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI 48202, USA
Department of Public Health Science, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI 48202, USA
Department of Otolaryngology, Henry Ford Hospital, 2799 W. Grand Blvd, Detroit, MI 48202, USA
Alexandria Clinical Oncology Department, Alexandria University, Qasm Bab Sharqi, Alexandria Governate, 00302, Egypt

Received 13 April 2018; received in revised form 17 September 2018; accepted 27 September 2018
Available online 11 January 2019

Abstract

Objectives: In patients with head and neck carcinoma, "treatment package time" (TPT) was proven to impact outcomes in cases receiving adjuvant radiotherapy alone. Its impact in patients receiving radiotherapy with concurrent systemic therapy has not been studied previously. The TPT influence on survival endpoints for patients treated with surgery followed by radiation and concurrent systemic therapy was analyzed.

Methods: Institutional database to identify head and neck carcinoma cases treated with definitive surgery followed by concomitant chemo(bio) radiotherapy (CRT) was used. TPT was the number of days elapsed between surgery and the last day of radiation. %FINDCUT SAS macro tool was used to search for the cutoff TPT that was associated with significant survival benefit. Kaplan–Meier curves, log-rank tests as well as univariate and multivariate analyses were used...
to assess overall survival (OS) and recurrence free survival (RFS).

Results: One hundred and three cases with a median follow up of 37 months were included in the study. Oropharyngeal tumors were 43%, oral cavity 40% and laryngeal 17% of cases. Concurrent systemic therapy included platinum and cetuximab in 72% and 28%, respectively. Optimal TPT was found to be < 100 days with significantly better OS ($P = 0.002$) and RFS ($P = 0.043$) compared to TPT $\geq 100$ days. On multivariate analysis; TPT $\leq 100$ days, extracapsular nodal extension, high-risk score, lymphovascular space and perineural invasion were independent predictors for worse OS ($P < 0.05$). T4, extracapsular nodal extension and high-risk score were all significantly detrimental to RFS ($P < 0.05$).

Conclusions: Addition of concomitant systemic therapy to adjuvant radiotherapy did not compensate for longer TPT in head and neck squamous cell carcinoma. Multidisciplinary coordinated care must be provided to ensure the early start of CRT with minimal treatment breaks.

Copyright © 2018 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

### Introduction

Head and neck squamous cell carcinomas (HNSCC) constitute a major problem in the United States with approximately 64,490 new cases and 13,740 deaths expected in 2018. More than 75% of cases present with localized or regional disease with 5 year survival of around 80% and 60% for localized and regional disease respectively. Combined modality therapy with surgery and postoperative radiation therapy (PORT) is recommended for a great proportion of patients as it had been proven to be better than surgery alone.3 Many studies have shown TPT (time from surgery to RT initiation, overall radiotherapy duration due to treatment interruptions and delays) to be detrimental for locoregional control.14–16 As for surgery to radiotherapy initiation (SRT), improved outcomes were achieved with shorter wait times according to many studies.11,14–18 Other studies did not come to the same conclusion.19–22 A meta-analysis involving 851 patients reported that adjuvant RT should be initiated within 6 weeks of surgery for best results and this has been adopted by the NCCN.9,23 Finally, the concept of TPT emerged which encompasses the influence of the two aforementioned time components (SRT + ORT) and was proven to correlate with outcomes even when any or both of them were not.19,24–26 Optimal TPT cutoff varied between different studies with 100 days in classic studies19,25,26 ranging between 77 and 105 in others.27–30 In contrast, other studies refuted the significance of the TPT.12,13

Nevertheless, none of these studies analyzed time factors for cases treated using adjuvant radiation therapy with concomitant systemic therapy. In the present study we investigated the influence of TPT on outcomes of a high-risk population of surgically resected head and neck squamous cell carcinoma treated by adjuvant chemoradiotherapy.

### Methods

After obtaining Institutional Review Board approval, we queried our prospectively maintained head and neck cancer database to identify HNSCC cases of oral cavity, oropharynx and larynx/hypopharynx treated with curative intent by surgical resection followed by adjuvant CRT. The decision to add CT to PORT was undertaken in the setting of multidisciplinary tumor board based mainly on close/involved margin and/or ECE in surgical specimen.5–8 All cases without curative intent surgery, those treated with adjuvant radiotherapy alone as well as patients receiving induction chemotherapy were excluded from our analysis. In addition, cases who had not received the planned RT dose or systemic therapy cycles were not included. Patients were preferentially recommended concurrent cisplatin. Concurrent cetuximab was delivered in patients who could not tolerate cisplatin due to pre-existing renal, cardiac or hearing issues. For each case we calculated a provisional risk score (RS) based on NCCN defined indications for adjuvant treatment. Seven points were assigned for PM and ECE and 1 point for each of the remaining adverse features (T3/4, N2+, PNI and LVSI) reaching a maximum possible score of 8. We then categorized RS as low (<2), intermediate (2–4) and high (4–8). We did not include nodal involvement of level IV and V as this factor is not prognostic for laryngeal/hypopharyngeal tumors that we
Table 1  Demographic, pathologic and treatment characteristics of the two study groups with TPT<100 days or TPT≥100 days.

| Variable                        | TPT <100 days (n = 62) | TPT ≥ 100 days (n = 41) | P value |
|---------------------------------|------------------------|-------------------------|---------|
| Median age in years             | 59 (range 36.0–84.0)   | 56 (range 36.0–79.0)    | 0.401   |
| Gender                          |                        |                         | 0.091   |
| Male                            | 50 (81%)               | 27 (66%)                |         |
| Female                          | 12 (19%)               | 14 (34%)                |         |
| Race                            |                        |                         | 0.622   |
| White                           | 39 (63%)               | 25 (60%)                |         |
| Black and others                | 23 (37%)               | 16 (40%)                |         |
| Smoking status                  |                        |                         | 0.012   |
| Non-smoker                      | 22 (35%)               | 4 (10%)                 |         |
| Smoker ≤ 20 packs years         | 11 (18%)               | 12 (29%)                |         |
| Smoker > 20 packs years         | 29 (47%)               | 25 (61%)                |         |
| Alcohol status                  |                        |                         | 0.481   |
| None                            | 21 (34%)               | 12 (29%)                |         |
| Social drinker/infrequent       | 20 (32%)               | 18 (44%)                |         |
| Alcoholism                      | 21 (34%)               | 11 (27%)                |         |
| Charlson comorbidity score      |                        |                         | 0.0572  |
| 0                               | 32 (52%)               | 18 (44%)                |         |
| 1-2                             | 18 (29%)               | 16 (39%)                |         |
| 3+                              | 12 (19%)               | 7 (17%)                 |         |
| HNSCC location                  |                        |                         | 0.002   |
| Oral cavity                     | 19 (31%)               | 22 (54%)                |         |
| Oropharynx                      | 35 (56%)               | 9 (22%)                 |         |
| Larynx/hypopharynx              | 8 (13%)                | 10 (24%)                |         |
| HPV status                      |                        |                         | 0.311   |
| Positive                        | 17 (27%)               | 6 (15%)                 |         |
| Negative                        | 12 (19%)               | 9 (22%)                 |         |
| Not-tested                      | 33 (53%)               | 26 (63%)                |         |
| Histological grade              |                        |                         | 0.167   |
| 1                               | 13 (21%)               | 5 (13%)                 |         |
| 2 & 3                           | 49 (79%)               | 36 (87%)                |         |
| Pathological T stage            |                        |                         | 0.033   |
| T1/2                            | 29 (47%)               | 13 (32%)                |         |
| T3                              | 7 (11%)                | 3 (7%)                  |         |
| T4                              | 26 (42%)               | 25 (61%)                |         |
| Pathological N stage            |                        |                         | 0.668   |
| NO/N1                           | 19 (31%)               | 10 (25%)                |         |
| N1/N2                           | 43 (69%)               | 31 (75%)                |         |
| Median +ve LN<sup>c</sup>        | 2 (0–20)               | 3 (0–91)                | 0.282   |
| +ve ECE<sup>d</sup>             | 30 (48%)               | 25 (61%)                | 0.210   |
| Final surgical margins          |                        |                         | 0.289   |
| Negative                        | 25 (40%)               | 23 (56%)                |         |
| Close                           | 15 (24%)               | 7 (17%)                 |         |
| Involved                        | 22 (36%)               | 11 (27%)                |         |
| +ve LVI<sup>f</sup>             | 24 (39%)               | 20 (49%)                | 0.312   |
| +ve PNI<sup<g</sup>             | 24 (39%)               | 24 (59%)                | 0.048   |
| Mean risk score (RS, Mean ± SD) | 3.7 ± 1.6              | 4.3 ± 2.1               | 0.155   |
| Concomitant systemic treatment  |                        |                         | 0.122   |
| Platinum based                  | 48 (77%)               | 26 (63%)                |         |
| Cetuximab                       | 14 (23%)               | 15 (37%)                |         |
| LN dissection                   |                        |                         | 0.036   |
| Unilateral                      | 27 (44%)               | 9 (22%)                 |         |
| Bilateral                       | 35 (56%)               | 32 (78%)                |         |
| RT<sup>†</sup> treatment interruptions | 7 (11%)           | 15 (37%)                | 0.002   |
| Median time to recurrence (months) | 8                | 6                      | 0.171   |
| Alive at last follow up         | 48 (77%)               | 20 (49%)                | 0.003   |

<sup>a</sup> Head and neck squamous cell carcinoma.

<sup>b</sup> Human papilloma virus.

<sup>c</sup> Positive.

<sup>d</sup> LN dissection.

<sup>f</sup> Positive.
Treatment package time (TPT), representing the number of days elapsed between surgery date and the last day of CRT was calculated for each case of the study cohort. We used %FINDCUT SAS macro tool to define TPT optimal cutoff point to the nearest 10 days that was correlated with the most significant difference in overall survival (OS) and recurrence free survival (RFS). \(^{31,32}\) After establishment of the cutoff value 2 groups were created and all demographic, pathological and treatment data was compared.

Chi-squared and Fisher’s Exact tests for categorical and Wilcoxon test for continuous variables were performed to analyze differences in distribution of variables by TPT cutoff, with the generation of two-sided \(P\) analyze differences in distribution of variables by TPT Wilcoxon test for continuous variables were performed to compared.

Mean RS was 4.0 ± 1.8 (median 4). All cases received a complete RT course to the tumor bed and neck using intensity modulated radiation treatment (IMRT) prescribed to complete RT course to the tumor bed and neck using intensity modulated radiation treatment (IMRT) prescribed to the PTV. High dose regions received 60–66 Gy with low risk areas receiving 45–54 Gy. All cases received 2 Gy per fraction, five fractions per week with median dose 65 Gy, mean (62.5 ± 6.6) Gy concomitant with either platinum based chemotherapy (72%) or cetuximab (28%). Median TPT for the entire study cohort was 91 (57–168) days and mean was (95.8 ± 24.0) days.

Using the %FINDCUT SAS macro tool we evaluated 80, 90, 100 and 110 days as cutoff points for TPT. Optimal TPT was found to be < 100 days (\(n = 62\)) with significantly better OS (\(P = 0.002\)) and RFS (\(P = 0.043\)) compared to TPT ≥ 100 days (\(n = 41\)). The two study groups were well-balanced for the majority of demographic and pathological features including RS (mean: 3.7 vs 4.3; \(P = 0.15\)) except that TPT ≥ 100 days was associated with higher smoking history, OC location, T4 disease and bilateral neck dissection (\(P < 0.05\)). TPT < 100 days had less interruptions during RT and significantly more oropharyngeal cases (\(P = 0.002\)); nevertheless, there was no difference in the distribution of HPV positive and negative disease between the two study groups (\(P = 0.31\)) as portrayed in Table 1. Causes for TPT > 100 days were RT interruptions (15; 37%) and/or longer surgery to RT initiation (34; 83%) as portrayed in Table 2.

After a median follow up time of 37 months (3–72); nearly a third of the population (31%) had a recurrence most of which (78%) included distant metastases that were fatal. Salvage surgeries with or without re-irradiation were performed only in 6 subjects (18.8%) and the remaining cases either received palliative systemic therapy (37.4%) or only supportive measures (43.8%). Kaplan–Meier curve for OS shows significant benefit for TPT < 100 days at 1 & 2 years [91% (95% CI: 82–97) vs. 68% (95% CI: 52–80) & 90% (95% CI: 79–95) vs. 56% (95% CI: 39–69), \(P < 0.01\)] as in Fig. 1A. Similar findings were detected for RFS with TPT < 100 days at 1 & 2 years [89% (95% CI: 78–94) vs. 71% (95% CI: 54–82) & 80% (95% CI: 68–88) vs. 60% (95% CI: 44–74), \(P < 0.05\)] as depicted in Fig. 1B.

Meanwhile, subgroup analyses showed that two-year OS was worse for TPT ≥ 100 vs < 100 days for both oral cavity (\(P = 0.03\)) and oropharynx (\(P = 0.02\)) Similar findings were detected among both smokers (\(P = 0.003\)) or non-smokers (\(P = 0.02\)). This significant difference persisted within cases that received platinum after we excluded cases that utilized cetuximab (\(P = 0.002\)). A secondary analysis for risk score categories expressed a highly significant detrimental effect on OS and RFS for higher RS (\(P < 0.0001\)) as in Fig. 2.

On MVA for OS for the whole cohort (\(n = 103\)); TPT > 100 days and high RS were independent predictors for worse OS (\(P < 0.05\)) after adjusting for all other factors. In another MVA model including RS components and excluding RS total score: ECE, LVI & PNI were all detrimental for OS (\(P < 0.05\)) as shown in Table 3. In an exploratory MVA for RFS: T4 vs T1/2, +ve ECE and high RS were significantly related to

| Table 2 | Causes of TPT ≥ 100 days [%]. |
| --- | --- |
| Overall causes of TPT ≥ 100 days (\(n = 41\)) | N (%)|
| Long SRT\(^{a}\) | 26 (71)|
| RT treatment interruptions | 7 (17)|
| Long SRT and RT treatment delays | 8 (12)|
| Causes of long SRT\(^{b} (n = 34)\) | |
| Wound healing problems | 21 (62)|
| Insurance and socioeconomic issues | 10 (29)|
| Medical comorbidities | 3 (9)|

\(^{a}\) Treatment package time.
\(^{b}\) Surgery to radiation therapy interval.
\(^{c}\) Radiation therapy.
inferior RFS ($P < 0.05$); however, TPT was not independently associated with RFS.

**Discussion**

To our knowledge, this is the first analysis examining timing factor for patients treated with postoperative radiotherapy utilizing modern IMRT technique with concurrent systemic therapy. Harris et al in a recently published national cancer database (NCDB) study which included more than 25 000 HNSCC cases treated with adjuvant RT, comprised 57% cases that received concomitant chemotherapy. Nevertheless, only SRT interval was studied and no separate analysis was provided for the cases only treated with adjuvant CRT. Cases managed with adjuvant CRT represented 43% ($n = 118$) of Tribius et al study, albeit no separate results for TPT < or ≥87 days were presented for this subgroup.

We hypothesized that higher total dose 60–66 Gy and sensitizing concomitant systemic therapy will achieve an acceptable level of locoregional control and survival independent of TPT. However, TPT < 100 days was proven to have superior overall and recurrence free survival and this cutoff time point was not much different from the 87–100 days that prevailed in classic studies. TPT of 87 days was calculated in modern series in Tribius et al that included CRT cases and the most recent report on the MD Anderson randomized trial of PORT and both resorted to recursive partitioning analysis to determine the cutoff level. TPT ≥ 100 days was independently associated with worse OS but not for RFS. This may be as the MVA model for RFS was only exploratory due to inadequate recurrence events which was not the case for OS.

In fact, sequential CT before RT yielded no benefit in terms of OS or DFS compared to PORT alone as per Intergroup 0034 study that was mainly owing to increased treatment package time in chemotherapy arm by at least 9 weeks. Similar outcomes for sequential CT were reported by Muriel et al, taking into consideration that chemotherapy was only effective in the CRT setting as long as RT starts within maximum of 8 weeks per inclusion criteria for the RTOG 95-01 study. RTOG 0024 also examined both short postoperative and concomitant CT without increasing TPT; however no superior results were attained compared
Table 3  Multivariable analysis models for predictors of recurrence free survival and overall survival for the entire study cohort (n = 103) including all components of RS and excluding RS (A), including RS as continuous or categorical and excluding its components (B).

| Variable                      | Response | Overall survival | Recurrence free survival |
|-------------------------------|----------|------------------|--------------------------|
|                               |          | HR               | 95% CI of HR | P value | HR | 95% CI of HR | P value |
| (A)                           |          |                  |              |         |    |              |         |
| ECE<sup>a</sup>               | Yes      | 2.92             | 1.35–6.33    | 0.0065  | 3.78| 1.56–9.11    | 0.0031 |
| LVSI<sup>b</sup>              | Yes      | 2.69             | 1.26–5.77    | 0.0108  | 2.22| 0.94–5.25    | 0.0687 |
| PNI<sup>c</sup>               | Yes      | 2.45             | 1.08–5.57    | 0.0319  | —  | —            | 0.0353 |
| Pathological T stage          | T1 vs T4 | —                | —            | —       | 0.19| 0.04–0.89    | 0.1384 |
|                               | T2 vs T4 | —                | —            | —       | 0.42| 0.14–1.32    | 0.2021 |
| (B)                           |          |                  |              |         |    |              |         |
| RS<sup>d</sup>               | Continuous | 1.53            | 1.28–1.83    | <0.0001 | 1.59| 1.29–1.95    | <0.0001 |
| RS category                   | High vs Low | 11.54          | 3.36–39.64   | 0.0001  | 9.05| 2.1–38.95    | 0.0031 |
|                               | Intermediate vs Low | 2.92       | 0.75–11.42   | 0.1229  | 2.93| 0.61–13.96   | 0.1777 |
| TPT<sup>e</sup>              | ≥100 vs 100 | 2.37            | 1.17–4.83    | 0.0170  | 1.6 | 0.78–3.31    | 0.2021 |

<sup>a</sup> Extracapsular nodal extension.

<sup>b</sup> Lymphovascular space invasion.

<sup>c</sup> Perineural invasion.

<sup>d</sup> Treatment package time.

<sup>e</sup> Risk score.
to RTOG 95–01 controls except in cases with ECE or PM.\textsuperscript{7,35} Consequently, both the theoretical postoperative proliferation of residual tumor cells as well as the rapid repopulation occurring during RT does not seem to be robustly counteracted by CT neither in the sequential setting nor concurrently with RT especially if long gaps occur. TPT has two components namely surgery to RT interval (SRT) and interruption occurring during the course of RT. In our study TPT $\geq$ 100 days was associated with more delays during RT (37% vs 11%, $P = 0.002$). Moreover, prolonged SRT was identified in 83% of TPT $\geq$ 100 days mainly due to wound healing problems (62%) or insurance issues and other medical conditions (38%). This is in agreement with factors associated with for longer TPT reported in other studies.\textsuperscript{25,30} It is noteworthy to report that T4 disease and oral cavity location were more associated with longer TPT in our results as these cases are managed with more extensive surgery resulting in higher chances of complicated wound healing that is even worsened by higher smoking index that prevailed in that group. T4 disease, insurance and facility issues as well as the use of concomitant chemotherapy were all significantly associated with prolonged TPT as seen in our study.\textsuperscript{12,14,25} Whether adjuvant CRT should commence before maximal healing needs to be examined in a prospective setting. Nevertheless, robust pre-operative optimization in addition to adequate perioperative care need to be stressed as both will help in getting the patients through treatment as early as possible and hence limiting total package time.

Another crucial observation in our work in high risk population is that there was significant difference in outcomes among groups harboring multiple compared to fewer NCCN indications for RT $\pm$ CT as manifested in our provisional risk score (RS) which was independent of any other factors. Other studies that grouped cases according to number or weighting of risk factors confirmed this finding.\textsuperscript{13,25,27,36} Moreover, none utilized concomitant chemotherapy and most used suboptimal doses of RT. This finding persisted in our study despite the receipt of standard of care with currently recommended dosage and fractionation of RT and concomitant CT. Consequently, new trials need to be designed to address cases with multiple risk factors including those with ECE and involved margins to explore further dose escalation or other treatment options for this group.

Some limitations of this study ought to be mentioned. As with any non-randomized retrospective study, selection and reporting bias limit the study. However due to ethical reasons no prospective trial can be designed to explore the timing factors. Although the time frame of this study is nearly 6 years, treatment recommendations have not changed much during that time. Having relatively low number of cases prevented us from designing robust subgroup analyses for different HNSCC subsites bearing in mind that we had proportionally fewer larynx cases as laryngeal preservation is sought as possible. However, this is a single institution study and this high risk population is often low in number. Although TPT $\geq$ 100 days was associated with significantly less oropharyngeal cancers and more T4 disease, longer TPT was detrimental on OS after adjusting for all other factors. Neither tumor location nor T-stage were independent factors for OS in our study and also HPV status was not significantly different among study groups.

**Conclusion**

Addition of concomitant systemic therapy to adjuvant RT did not compensate for longer TPT in HNSCC with high risk features. Multidisciplinary coordinated care and support programs must be provided to ensure as early as possible start of CRT with minimal treatment breaks. The coexistence of multiple surgical and pathological risk factors is related to worse outcomes and this population needs to be encountered in the setting of dedicated prospective studies.

**Conflict of interest**

Corresponding: Ahmed I Ghanem MD: None. Matthew Schymick: None. Souheyla Bachiri MD: None. Aniruddh Mannari: None. Jawad Sheqwara, MD: None. Charlotte Burmeister MS: None. Steven Chang MD: None. Tamer Ghanem MD, PhD: None. Farzan Siddiqui MD, PhD: Henry Ford Hospital Department of Radiation Oncology receives research funding from Varian Medical Systems, Inc and Philips Medical, Varian Medical System Inc: Honoraria, Travel Expenses, Wayne State University: Honoraria, American College of Radiology Site surveyor for accreditation: Honoraria.

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
2. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975-2014. Bethesda, MD: National Cancer Institute: 2016. Available at: https://seer.cancer.gov/csr/1975-2014/. Accessed April 12, 2018.
3. Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M. Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Biol Phys. 1992;23:737–742.
4. Lundahl RE, Foote RL, Bonner JA, et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys. 1998;40:529–534.
5. Vikram B, Strong EW, Shah JP, Spiro R. Failure at the primary site following multimodality treatment in advanced head and neck cancer. Head Neck Surg. 1984;6:720–723.
6. Bernier J, Domene C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945–1952.
7. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937–1944.
8. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy.
trials of the EORTC (#22931) and RTOG (# 9501). *Head Neck*. 2005;27:843–850.

9. **NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers, Version 1;** 2018. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed April 11, 2018.

10. Salama JK, Saba N, Quon H, et al. ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. *Oral Oncol*. 2011;47:554–559.

11. Suwinski R, Sowa A, Wydmanski J, Tarnawski R, Maciejewski B. Time factor in postoperative radiotherapy: a multivariate locoregional control analysis in 868 patients. *Int J Radiat Oncol Biol Phys*. 2003;56:399–412.

12. Fujiwara RJ, Judson BL, Yarbrough WG, Husein Z, Mehra S. Treatment delays in oral cavity squamous cell carcinoma and association with survival. *Head Neck*. 2017;39:639–646.

13. Langendijk JA, de Jong MA, Leemans CR, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. *Int J Radiat Oncol Biol Phys*. 2003;57:693–700.

14. Shalik T, Handorf EA, Murphy CT, Mehra R, Ridge JA, Galloway TJ. The Impact of radiation treatment time on survival in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2016;96:975–975.

15. Trotti A, Klotch D, Endicott J, Ridley M, Cantor A. Post-operative accelerated radiotherapy in high-risk squamous cell carcinoma of the head and neck: long-term results of a prospective trial. *Head Neck*. 1998;20:119–123.

16. Vikram B. Importance of the time interval between surgery and postoperative radiation therapy in the combined management of head & neck cancer. *Int J Radiat Oncol Biol Phys*. 1979;5:1837–1840.

17. Ampil FL, Buechter KJ, Bairnsfather LE, Shockley WW. Timing and dosage of postoperative radiotherapy for squamous cell carcinoma of the upper aerodigestive tract. *J Oral Maxillofac Surg*. 1993;51:1194–1197.

18. Harris JP, Chen MM, Orosco RK, Sirjani D, Divi V, Hara W. Association of survival with shorter time to radiation therapy after surgery for US patients with head and neck cancer. *JAMA Otolaryngol Head Neck Surg*. 2018;144:349–359.

19. Schiff PB, Harrison LB, Strong EW, et al. Impact of the time interval between surgery and postoperative radiation therapy on locoregional control in advanced head and neck cancer. *J Surg Oncol*. 1990;43:203–208.

20. Parsons JT, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. An analysis of factors influencing the outcome of postoperative irradiation for squamous cell carcinoma of the oral cavity. *Int J Radiat Oncol Biol Phys*. 1997;39:137–148.

21. Bastit L, Blot E, Debourdeau P, Menard J, Bastit P, Le FR. Influence of the delay of adjuvant postoperative radiation therapy on relapse and survival in oropharyngeal and hypopharyngeal cancers. *Int J Radiat Oncol Biol Phys*. 2001;49:139–146.

22. van Harten MC, de Ridder M, Hamming-Vrieze O, Smeele LE, Balm AJ, van den Brekel MW. The association of treatment delay and prognosis in head and neck squamous cell carcinoma (HNSCC) patients in a Dutch comprehensive cancer center. *Oral Oncol*. 2014;50:282–290.

23. Huang J, Barbera L, Brouwers M, Brownman G, Mackillop WJ. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. *J Clin Oncol*. 2003;21:555–563.

24. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer: the time factor. *Int J Radiat Oncol Biol Phys*. 1997;39:831–836.

25. Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. *Head Neck*. 2002;24:115–126.

26. Le TC, Jung GM, Borel C, Bronner G, Flesch H, Velten M. Prognostic factors of survival in head and neck cancer patients treated with surgery and postoperative radiation therapy. *Acta Otolaryngol*. 2008;128:706–712.

27. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. *Int J Radiat Oncol Biol Phys*. 2001;51:571–578.

28. Dietl B, Schäfer C, Kölli O. The prognostic value of time parameters in adjuvant radiotherapy of head and neck cancer. A retrospective analysis of 138 patients. *Strahlenther Onkol*. 2005;181:800–807. Discussion 808–809.

29. Tribuk S, Donner J, Pazdyka H, et al. Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. *Head Neck*. 2016;38:1058–1065.

30. Rosenthal DI, ASR M, Garden AS, et al. Final report of a prospective randomized trial to evaluate the dose-response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2017;98:1002–1011.

31. Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint determination methods in survival analysis using SAS. In: *Proceedings of the 28th SAS Users Group International Conference (SUGI)*. 2003:261.

32. Meyers JP, Mandrekar JN. Cutpoint determination methods in survival analysis using SAS®: updated %FINDCUT macro. *Proc SAS Glob Forum*. 2015:3249.

33. Laramore GE, Scott CB, al-Sarraf M, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. *Int J Radiat Oncol Biol Phys*. 1992;23:705–713.

34. Muriel VP, Tejada MR, de Dios Luna del Castillo J. Time-dose-response relationships in postoperatively irradiated patients with head and neck squamous cell carcinomas. *Radiother Oncol*. 2001;60:137–145.

35. Rosenthal DI, Harris J, Forastiere AA, et al. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RT0G 0024. *J Clin Oncol*. 2009;27:4727–4732.

36. Sanguineti G, Richetti A, Bignardi M, et al. Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. *Int J Radiat Oncol Biol Phys*. 2005;61:762–771.

Edited by Jing Li